Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
- Sector: Healthcare
- Industry: Biotechnology
- Full Time Employees: 22
- Founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. in April 2003
- Headquartered in Framingham, Massachusetts
- http://www.pulmatrix.com
IPO: March 7, 2014
Nov 13, 2024: Pulmatrix, Inc. (NASDAQ:PULM) announced a definitive merger agreement with Cullgen Inc.